Transaction overview
LongueVue Capital (LVC), a private equity firm based in New Orleans, has made an investment in Apex Dental Laboratory Group (Apex), a leading dental laboratory platform serving dental practices across the United States. The transaction was completed on March 31, 2026, with Swaney Group Capital (SGC) also participating as an investor. Founded in 2015 and headquartered in Waco, Texas, Apex operates a national network of 16 laboratories spread across 12 states and employs around 400 employees. The company is known for its focus on innovation, domestic manufacturing, and customer service excellence.
Deal structure and financing
While the exact deal value and equity/debt split were not disclosed, Brown Gibbons Lang & Company served as the financial advisor to LVC in this transaction. Abacus Finance provided senior debt financing to support the investment. Norton Rose Fulbright LLP acted as legal counsel for LVC, while Sheppard, Mullin, Richter & Hampton LLP advised Apex on legal matters. The structure of the deal indicates that both equity and leverage were used to fund the acquisition, though specific details about seller retained stake or lock-up terms are not available.
Strategic context
LVC's investment in Apex aligns with its strategy to expand into healthcare by acquiring companies that offer meaningful value to patients and providers through innovative products and services. This move underscores LVC’s commitment to partnering with businesses that can leverage operational improvements and technological advancements to drive sustainable growth. For Apex, the partnership provides access to capital needed for further expansion and investment in technology and talent, while also bringing in experienced industry professionals like Bill Braun as an operating partner.
Regulatory path
Given the nature of the transaction involving a healthcare-related company but without specific disclosure of regulatory hurdles or approval processes, it is likely that this deal did not trigger significant regulatory scrutiny due to its private equity investment structure and non-public nature. However, given Apex's operations across multiple U.S. states, there may have been state-level health department or dental board reviews depending on the extent of compliance requirements in each jurisdiction.
The partnership between LVC and SGC, along with the involvement of industry expert Bill Braun, suggests a focus on operational enhancement and value creation rather than market dominance concerns that might necessitate antitrust filings. As such, this transaction appears to have navigated regulatory processes efficiently without public disclosure requirements or notable delays due to regulatory challenges.